Travere Therapeutics, Inc. (TVTX) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Travere Therapeutics presents strong short-term growth backed by record sales and patient starts for FILSPARI, imminent FDA approval for FSGS indication with January 2026 expected, positive Phase 3 DUPLEX study data, improving liquidity, and strong technical momentum with a recent 14% share rally.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Liquidity cushion ⢠Margin strength ⢠Cash burn TVTX has strong near-term liquidity and exceptional gross margins, but persistent operating losses, negative free cash flow, and meaningful leverage keep the investment case high risk.
Price Behavior
Key Price Behavior Insights: ⢠Higher low ⢠Key support ⢠Breakout needed Support Level: $42.96â$43.50 Resistance Level: $47.76 TVTX remains mildly bullish but fragile, with price holding above last month's starting point, support near $42.96â$43.50, and a clean breakout only if it reclaims $47.76.
Sentiment & News
Key News Insights: ⢠Civorebrutinib deal ⢠FILSPARI protection ⢠Durable proteinuria Travere's recent updates were broadly positive, led by a major civorebrutinib licensing deal, added FILSPARI patent protection, and supportive long-term kidney-disease data.
AI Summary
Travere has shifted from a speculative kidney-data story to a credible commercial growth thesis with FILSPARI expansion and durable demand, but the investment now hinges on proving sustained revenue growth can outpace heavy cash burn, debt, and dilution risk before the rerating runs out of room.
Description
Travere Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes therapies for rare diseases. Its marketed portfolio includes treatments for bile acid disorders and a drug for cystinuria, while its pipeline comprises a Phase III program for kidney diseases and an investigational enzyme-replacement candidate for classical homocystinuria. The company conducts partnered research with the NIH and patient organizations on rare genetic conditions, was renamed from Retrophin in 2020, and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 29 | Jan 5 | TVTX | Travere Therapeutics, Inc. | Travere Therapeutics presents strong short-term growth backed by record sales and patient starts for FILSPARI, imminent FDA approval for FSGS indication with January 2026 expected, positive Phase 3 DUPLEX study data, improving liquidity, and strong technical momentum with a recent 14% share rally. | Closed | -2.0% |